Antibiotics Can Be Used During Durvalumab Treatment in Biliary Tract Cancer

Antibiotics can be administered without compromising treatment efficacy in patients receiving a durvalumab-based regimen for advanced biliary tract cancer (BTC), researchers reported at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (abstract 550). The researchers analyzed data from a large study of patients treated with durvalumab (Imfinzi, AstraZeneca) plus chemotherapy or placebo plus chemotherapy, and found there was no difference in the growth, spread or